Expertise in
25
conditions

Dr. Mohamad O. Khawandanah

Hematology
Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic
800 NE 10th St, 
Oklahoma City, OK 
Accepting New Patients
13 Years of Experience
Expertise in
25
conditions
Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic
800 NE 10th St, 
Oklahoma City, OK 

Overview

Mohamad Khawandanah is a Hematologist practicing medicine in Oklahoma City, Oklahoma. He has been practicing medicine for over 13 years.

Dr. Khawandanah is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 6 clinical trials. Dr. Khawandanah is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OK

Hospital Affiliations

Duncan Regional Hospital, Inc
Norman Regional
Mercy Hospital Oklahoma City, Inc
O U Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic
800 NE 10th St, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Ixazomib Citrate, Lenalidomide
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
View 5 Less Clinical Trials

27 Total Publications

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.
Journal: Blood
Published: March 18, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sami Ibrahimi is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Ibrahimi is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ibrahimi is currently accepting new patients.

Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Asch is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Asch is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Asch is currently accepting new patients.

Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Referral may be required

SSM Health Cancer Care

1000 N. Lee Ave., 
Oklahoma City, OK 
 (1.4 miles away)
405-228-7100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Board certified in medical oncology, Todd Kliewer, MD is a physician in the Frank C. Love Cancer Institute at SSM Health St. Anthony Hospital - Oklahoma City and SSM Health Cancer Care in Midwest City. He treats patients in two convenient locations in Midtown Oklahoma City and Midwest City. Dr. Kliewer is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Breast Cancer. Dr. Kliewer is board certified in Oklahoma State Board Of Medical Licensure & Supervision, American Board Of Internal Medicine/Medical Oncology , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . Dr. Kliewer is currently accepting new patients.

Frequently Asked Questions about Dr. Mohamad O. Khawandanah

How do I make an appointment with Dr. Mohamad O. Khawandanah?

You can book an appointment with Dr. Mohamad O. Khawandanah by calling their office at 405-271-8299. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohamad O. Khawandanah a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohamad O. Khawandanah is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohamad O. Khawandanah specialize in?

While Dr. Mohamad O. Khawandanah is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Hodgkin Lymphoma, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mohamad O. Khawandanah participate in research or clinical trials?

Yes. Dr. Mohamad O. Khawandanah has published 27 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Mohamad O. Khawandanah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohamad O. Khawandanah accept my insurance?

Dr. Mohamad O. Khawandanah accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 405-271-8299 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khawandanah's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile